Anti–IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL) A Placebo-controlled, Double-Blind Study

American Journal of Respiratory and Critical Care Medicine

Volumn 199, Issue 4, 2019, Pages 508-517

  Sabogal Piñeros, Yanaika S ^a   Bal, Suzanne M ^a   van de Pol, Marianne A ^a   Dierdorp, Barbara S ^a   Dekker, Tamara ^a   Dijkhuis, Annemiek ^a   Brinkman, Paul ^a   van der Sluijs, Koen F ^a   Zwinderman, Aeilko H ^a   Majoor, Christof J ^a   Bonta, Peter I ^a   Ravanetti, Lara ^a   Sterk, Peter J ^a   Lutter, René ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Exacerbation; Loss of asthma control; Mepolizumab; Rhinovirus 16 challenge

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MEPOLIZUMAB; MYELOPEROXIDASE; SECRETORY IMMUNOGLOBULIN; TRYPTASE; VASCULOTROPIN; VASCULOTROPIN A; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA CONTROL QUESTIONNAIRE; B LYMPHOCYTE; BRONCHOALVEOLAR LAVAGE FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MACROPHAGE; MALE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RHINOVIRUS; RHINOVIRUS INFECTION; SPUTUM ANALYSIS; VIRUS LOAD; YOUNG ADULT; ASTHMA; COMPLICATION; CYTOLOGY; IMMUNOLOGY; PICORNAVIRUS INFECTION; VIROLOGY; VITAL CAPACITY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; B-LYMPHOCYTES; BRONCHOALVEOLAR LAVAGE FLUID; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-5; MACROPHAGES; MALE; NEUTROPHILS; PICORNAVIRIDAE INFECTIONS; RHINOVIRUS; VITAL CAPACITY; YOUNG ADULT;

EID: 85056710355     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201803-0461OC     Document Type: Article

References (38)

1. Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. Mucosal Immunol 2015;8:464–475.
2. Handzel ZT, Busse WW, Sedgwick JB, Vrtis R, Lee WM, Kelly EA, et al. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol 1998;160:1279–1284.
3. Percopo CM, Dyer KD, Ochkur SI, Luo JL, Fischer ER, Lee JJ, et al. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood 2014;123:743–752.
4. Rosenberg HF, Domachowske JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol 2001;70:691–698.
5. Sikriwal D, Seth D, Parveen S, Malik A, Broor S, Batra JK. An insertion in loop L7 of human eosinophil-derived neurotoxin is crucial for its antiviral activity. J Cell Biochem 2012;113:3104–3112.
6. Samarasinghe AE, Melo RC, Duan S, LeMessurier KS, Liedmann S, Surman SL, et al. Eosinophils promote antiviral immunity in mice infected with influenza A virus. J Immunol 2017;198: 3214–3226.
7. Drake MG, Bivins-Smith ER, Proskocil BJ, Nie Z, Scott GD, Lee JJ, et al. Human and mouse eosinophils have antiviral activity against parainfluenza virus. Am J Respir Cell Mol Biol 2016;55: 387–394.
8. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol 2015;135:299–310, quiz 311.
9. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716–725.
10. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013;13:9–22.
11. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715–1721.
12. Eng SS, DeFelice ML. The role and immunobiology of eosinophils in the respiratory system: a comprehensive review. Clin Rev Allergy Immunol 2016;50:140–158.
13. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993.
14. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144–2148.
15. Ravanetti L, Dijkhuis A, Sabogal Pineros YS, Bal SM, Dierdorp BS, Dekker T, et al.; U-BIOPRED Study Group. An early innate response underlies severe influenza-induced exacerbations of asthma in a novel steroid-insensitive and anti-IL-5-responsive mouse model. Allergy 72:737–753.
16. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64–72.
17. Norzila MZ, Fakes K, Henry RL, Simpson J, Gibson PG. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. Am J Respir Crit Care Med 2000;161:769–774.
18. Sabogal Piñeros YS, Bal S, Van De Pol MA, Smids-Dierdorp B, Dekker T, Dijkhuis A, et al. Anti-IL5 treatment alters eosinophil responses to a rhinovirus-16 challenge in mild asthma patients and also that of neutrophils, macrophages and B cells [abstract]. Am J Respir Crit Care Med 2018;197:A1196.
19. Johansson MW, Activation states of blood eosinophils in asthma. Clin Exp Allergy 2014;44:482–498.
20. Brandtzaeg P. Secretory IgA: designed for anti-microbial defense. Front Immunol 2013;4:222.
21. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006;117: 1277–1284.
22. Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, et al. The innate immune cross talk between NK cells and eosinophils is regulated by the interaction of natural cytotoxicity receptors with eosinophil surface ligands. Front Immunol 2017;8:510.
23. Kim JH, Choi GE, Lee BJ, Kwon SW, Lee SH, Kim HS, et al. Natural killer cells regulate eosinophilic inflammation in chronic rhinosinusitis. Sci Rep 2016;6:27615.
24. Kelly EA, Esnault S, Liu LY, Evans MD, Johansson MW, Mathur S, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med 2017; 196:1385–1395.
25. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001;164: S39–S45.
26. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998;279:381–384.
27. Evans I, Dower SK, Francis SE, Crossman DC, Wilson HL. Action of intracellular IL-1Ra (type 1) is independent of the IL-1 intracellular signalling pathway. Cytokine 2006;33:274–280.
28. Zou H, Xu YJ, Zhang ZX. Effect of vascular endothelial growth factor and its receptor KDR on human airway smooth muscle cells proliferation. Chin Med J (Engl) 2005;118:591–594.
29. Kovalszki A, Weller PF. Eosinophilia in mast cell disease. Immunol Allergy Clin North Am 2014;34:357–364.
30. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817–827.
31. Gao J, Zhang M, Zhou L, Yang X, Wu H, Zhang J, et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2017;12:1287–1293.
32. George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis 2016;7:34–51.
33. Denburg JA, Sehmi R, Upham J, Wood L, Gauvreau G, O’Byrne P. Regulation of IL-5 and IL-5 receptor expression in the bone marrow of allergic asthmatics. Int Arch Allergy Immunol 1999;118:101–103.
34. Jogie-Brahim S, Min HK, Fukuoka Y, Xia HZ, Schwartz LB. Expression of a-tryptase and b-tryptase by human basophils. J Allergy Clin Immunol 2004;113:1086–1092.
35. Dijkstra D, Hennig C, Hansen G, Biller H, Krug N, Hohlfeld JM. Identification and quantification of basophils in the airways of asthmatics following segmental allergen challenge. Cytometry A 2014;85:580–587.
36. Dahl C, Hoffmann HJ, Saito H, Schiøtz PO. Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy 2004;59: 1087–1096.
37. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008;105:13562–13567.
38. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016;4: 549–556.